This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Incyte Corporation. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Aibin Zhang: Innovator in JAK1 Inhibition
Introduction
Aibin Zhang is a notable inventor based in Chester Springs, Pennsylvania. He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective inhibitors.
Latest Patents
Aibin Zhang holds a patent for processes of preparing a JAK1 inhibitor. The patent details the preparation of 4-[3-(cyanomethyl)-3-(3',5′-dimethyl-1H, 1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, along with its phosphoric acid salt. This compound is recognized for its utility as a selective Janus kinase 1 (JAK1) inhibitor, which is crucial in various therapeutic applications.
Career Highlights
Aibin Zhang is currently employed at Incyte Corporation, a leading biopharmaceutical company. His work focuses on innovative solutions in drug development, particularly in the area of targeted therapies.
Collaborations
Aibin collaborates with talented colleagues, including Jiacheng Zhou and Yingrui Dai, who contribute to the advancement of their shared research goals.
Conclusion
Aibin Zhang's work in developing JAK1 inhibitors showcases his commitment to innovation in the pharmaceutical industry. His contributions are paving the way for new therapeutic options in treating various diseases.